Contineum Therapeutics, Inc.
CTNM
$12.15
-$0.07-0.57%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 15.53% | 2.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.62% | -16.59% | |||
| Operating Income | -14.62% | 16.59% | |||
| Income Before Tax | -18.48% | 20.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.48% | 20.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.48% | 20.25% | |||
| EBIT | -14.62% | 16.59% | |||
| EBITDA | -14.67% | 16.68% | |||
| EPS Basic | -7.80% | 26.54% | |||
| Normalized Basic EPS | -7.81% | 26.53% | |||
| EPS Diluted | -7.80% | 26.54% | |||
| Normalized Diluted EPS | -7.81% | 26.53% | |||
| Average Basic Shares Outstanding | 9.90% | 8.57% | |||
| Average Diluted Shares Outstanding | 9.90% | 8.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||